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Purpose/Objective: In the Stereotactic Body Radiation 
Treatment (SBRT) of lung tumors with 3-D planning, designing 
an Internal Target Volume (ITV) framing the Gross Tumor 
Volumes (GTV) in different phases of the respiratory cycle 
can be modified in each treatment fraction, even losing 
coverage dose if there is any change in the position of the 
tumor or in the patient breathing pattern. 
Our objective was to analyze changes in the ITV between 
each fraction SBRT treatment and the dose and coverage 
achieved by this volume in each of the given fractions. 
Materials and Methods: We analyze 20 patients and 22 
treated lung lesions (primary/metastatic), aged from 57 to 84 
years. Simulation and design of volumes were done with the 
fusion of three CT studies in different respiratory phases: 
normal breathing, inspiration, expiration. This procedure was 
done in each fraction of treatment. Immobilization devices 
were used for stereotactic conditions (vacuum mattres; 
prostep system). Three GTV were delineated and one ITV was 
designed to frame the boundaries of the three GTV. Margin of 
5mm was added to the ITV for the Planning Target Volume 
(PTV). The first planned treatment (ITV_0_planning) was 
applied in every new volume designed in each fraction and 
modified if necessary, resulting one ITV for each fraction 
(ITV_1; ITV_2,…). SBRT treatment was delivered with linear 
accelerator CLINAC 2100 (Varian). 3D planning was performed 
with Pinnacle System software (Phillips). For the ITV 
coverage analysis and dosimetry we selected the 100% of the 
total prescribed dose. Conformal Index ranged between 1.2-
3.5. 
Results: The numbers of fractions administered: 1 fraction in 
two cases; 2 fractions in eight cases; 3 fractions in 12 cases. 
Maximum interfraction interval time was 48 hours, and 
minimum 24 hours. 
ITV volume interfraction variation: (fig. 1) 
Mean: 3,9cc; median: 2,6cc; min: 0,5; max: 16.7 
The relative variation to the ITV_0_planning volume: 
Mean: 26%; median: 22.5%; min: 2%; max: 68% 
ITV coverage (total prescribed dose) interfraction variation: 
(fig. 2) 
Mean: 5,3%; median: 2%; min: 0; max 2,5% 
In five cases (22.7%) the ITV coverage variation was ≥ 10%. 
 
 
Fig. 1. ITV interfraction variation (vol. cc) 
 
 
Fig. 2. ITV interfraction coverage 
 
Conclusions: There is a variation in the interfracción ITV in 
SBRT treatments. The percentage change in this volume 
regarding designed for treatment planning reaches an 
average of 26% of the initial volume ITV. Dosimetry from the 
initial planning (not modified for the new ITV´s) yielded a 
mean variation in the ITV interfraction coverage of 5.3%, 
which seems not excessive. In 78% of cases, the ITV coverage 
variation was within 90% of the total prescribed dose. In our 
practice, replanning despite variations ITV is not necessary, 
although there are cases where the total prescribed dose may 
fail to protect 100% of this volume. The Planning Target 
Volume (PTV) coverage and tolerance of organs at risk are 
those which define the need for change in the initial 
planning. 
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Purpose/Objective: Standard treatment for inoperable stage 
3 NSCLC is concurrent chemo-radiation (CRT). In busy centers 
such as ours, radiation treatment often cannot be started 
promptly. To prevent treatment delays, a regimen consisting 
of induction chemotherapy followed by CRT was developed. 
In the induction phase, carboplatin (C) and gemcitabine (G) 
are given. In the CRT phase, low-dose paclitaxel (P) and G 
were used for their known radio-sensitizing properties. This 
approach was initially tested in a phase II protocol between 
2003 and 2004 and continues to be routinely used at the 
McGill University Health Centre (MUHC). We report the long 
term outcomes with this regimen based on a pooled analysis 
of both protocol and non-protocol patients. 
Materials and Methods: Forty-one stage 3 NSCLC patients 
were treated on protocol between January 2003, and 
November 2004. The outcomes and toxicity data of an 
additional 101 stage 3 NSCLC patients treated off-protocol 
with the same regimen between December 2004 and August 
2013 at the MUHC were retrieved, giving a total of 142 
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patients: 80 males, 62 females, median age 64 (35-83), stage 
3A (83 pts) or 3B (59 pts). Patients received 2 cycles of C 
AUC=5 IV on day 1 and G 1000mg/m2 IV on days 1 and 8 every 
3 weeks x 2, followed on day 50 by CRT, 60Gy/30 over 6 
weeks, concomitantly with P 50mg/m2 IV and G 100mg/m2 IV 
on days 1 and 8 every three weeks x 2 cycles. 
Results: The median overall survival was 23 months. With a 
median follow-up of 54 months, the 3, 4 and 5 year overall 
survival was 37% (38 pts remaining), 27% (21 pts), and 23% (15 
pts) respectively. The median and 5 year progression-free 
survival rates were 11 months and 21% respectively. Rates of 
acute grade ≥ 3 hematological, esophageal and respiratory 
toxicity were, respectively, 20%, 8% and 7%. Forty-eight 
patients received further lines of chemotherapy. 
Conclusions: The results of the present analysis based on 142 
stage 3 NSCLC patients treated with this novel induction 
chemotherapy approach affirm its favourable toxicity profile 
without apparent compromise in clinical outcomes. Indeed, 
although the development of this regimen was motivated by 
delays to prompt commencement of CRT, the observed 
outcomes do compare favourably with those associated with 
immediate concurrent CRT regimens.  
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Purpose/Objective: Decision Support Systems, based on 
statistical prediction models, have the potential to change 
the way medicine is being practiced, but their application is 
currently hampered by the astonishing lack of impact studies. 
The main goal of this project aims to develop a scalable 
infrastructure to integrate translational research into the 
clinical decision making process in lung cancer.  
Materials and Methods: To develop this infrastructure, it was 
decided to use an integration based on free software tools. 
Among them, the management system for clinical trials, 
OpenClinica, provides mechanisms for the definition of 
electronic records and collection of cancer information 
relevant to research studies, as well as offers techniques for 
managing and maintaining the data. Additionally, for 
achieving a clinical decision support, we incorporated tools 
that provide mechanisms for data mining processes. The 
architecture also integrates a software for biomedical 
informatics research: i2b2. Information from different data 
sources such as the information recorded from the electronic 
health records of OpenClinica was stored centrally in a data 
warehouse. Finally, a tool integrates the mechanisms for 
analysis and data mining. Two different approaches are used 
for this task: RapidMiner to implement the algorithms of data 
mining and data analysis; and the business rule definition in 
JBoss Guvnor for process modeling in relation to the oncology 
clinical guide. With these two tools clinicians can receive 
recommendations based on both clinical data and decisional 
algorithms defined by international treatment guidelines. 
Results: The recruitment from January 1, 2013 until 
September 1, 2014 comprises the clinical data from 163 lung 
cancer patients treated with radio(chemo)therapy. Genetic 
data come from another operating system and includes 
genotypes at 3 single nucleotide polymorphisms of the HSPB1 
gene which has been found to be associated survival after 
using the data mining tool. Finally, the dosimetric data are 
exported from radiotherapy treatment planning systems. 
Currently, we are integrating the information mentioned 
before with the clinical decision support algorithms based on 
international treatment guidelines. 
Conclusions: The development of infrastructures based on 
the integration of systems able to interoperate between each 
other will favor the agile integration between the classical 
research and the clinical practice, allowing the customization 
of treatments.  
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Purpose/Objective: In patients treated with lung 
stereotactic body radiation therapy (SBRT), dynamic tumor 
tracking technique (DTT) can potentially improve accuracy of 
treatment and allow reduction of dose to the surrounding 
organs at risk (OARs). In Vero4DRT, the DTT can be 
performed by using its unique gimbaled linac system. The 
purpose of this study is to assess the technical advantages of 
DTT in lung SBRT when compared to treatment without DTT 
(static SBRT planning) on the Vero4DRT platform.  
Materials and Methods: Thirteen patients from our 
institution treated with lung SBRT with DTT by Vero4DRT 
between March 2013 and September 2014 were included in 
this study. All patients underwent the same planning process 
detailed below. For each patient, an SBRT plan without DTT 
was created using the same CT images and compared with 
the actual treatment plan. Prior to CT simulation, fiducial 
markers were inserted around the tumor via bronchoscopy. 
During CT simulation, a planning CT was first obtained in the 
expiratory phase using a respiratory gating system, followed 
by a 4D-CT scan. GTV was then delineated on the planning 
CT. For DTT SBRT, ITV was defined as GTV plus uncertainty of 
distances from the center of the GTV to the center of the 
fiducial markers calculated in all phases of 4D-CT. PTV (tPTV) 
was created by adding an individualized margin to account 
for uncertainties of 4D respiratory model and other 
mechanical errors. For static SBRT, ITV was the summation of 
GTV positions in all phases of 4D-CT, and the PTV (sPTV) was 
defined as ITV plus 5mm margin for set-up errors. The 
prescription dose was 50 Gy in 4 fractions (D95 prescription) 
to both tPTV and sPTV. To assess the technical advantage of 
DTT SBRT, the PTV volumes and V20 of the lung for both sets 
of plans were compared.  
Results: The median tumor diameter and respiratory motion 
in all patients was 30mm (12-48mm) and 17mm (4-31mm) 
respectively. The mean volumes of tPTV and sPTV were 
32.6ml and 49.8ml respectively, corresponding to an average 
reduction of 28.7 ± 8.0% (p = 0.0003) in the tPTV compared 
